Thomas T. Thomas is Director at OPIANT PHARMACEUTICALS, INC. (OPNT). They have made 4 open-market trades across 1 company since 2018, most recently 2023-03-02.
CIK 0001689819
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $25K since 2020, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OPNT | 2,000 | $41K |
Shares reported on the most recent Form 4, priced at the 2023-03-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OPNT | SELL · 10b5-1 | 2021-09-21 | 2021-09-23 | $24.54 | $38K | +8.5% | -12.0% | +31.8% |
| OPNT | SELL · 10b5-1 | 2021-09-14 | 2021-09-16 | $19.37 | $30K | +0.3% | +4.8% | +42.8% |
| OPNT | SELL · 10b5-1 | 2021-09-07 | 2021-09-09 | $18.00 | $15K | +45.2% | +53.4% | +81.3% |
| OPNT | SELL | 2021-08-19 | 2021-08-20 | $16.22 | $16K | +4.8% | +43.2% | +43.3% |
| OPNT | BUY | 2020-09-03 | 2020-09-08 | $8.34 | $25K | +8.0% | -5.8% | +7.2% |
| OPNT | SELL | 2018-05-16 | 2018-05-18 | $16.44 | $45K | +1.3% | -4.8% | -3.4% |
| OPNT | SELL | 2018-05-14 | 2018-05-15 | $18.35 | $79K | -7.6% | -11.7% | -8.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.